PHATHOM PHARMACEUTICALS, INC.

Analyst Reco. Phathom Pharmaceuticals, Inc.

Equities

PHAT

US71722W1071

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
10.54 ^USD	-1.40%		+4.46%	+15.44%

May. 09	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target	May. 03	MT
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating	Jan. 05	MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating	Nov. 03	MT
HC Wainwright Initiates Coverage on Phathom Pharmaceuticals with Buy Rating, $28 Price Target	23-08-09	MT
Craig-Hallum Starts Phathom Pharmaceuticals at Buy With $21 Price Target	23-03-13	MT
BMO Capital Adjusts Price Target on Phathom Pharmaceuticals to $30 From $35, Maintains Outperform Rating	23-03-01	MT
Needham Adjusts Price Target on Phathom Pharmaceuticals to $23 From $25, Maintains Buy Rating	23-02-10	MT
BMO Capital Trims Price Target on Phathom Pharmaceuticals to $35 From $38, Affirms Outperform Rating	23-01-04	MT
Needham Adjusts Phathom Pharmaceuticals Price Target to $25 From $38, Maintains Buy Rating	23-01-04	MT
BMO Capital Cuts Price Target on Phathom Pharmaceuticals to $38 From $45, Maintains Outperform Rating	22-11-14	MT
Guggenheim Adjusts Price Target on Phathom Pharmaceuticals to $30 From $42, Maintains Buy Rating	22-11-11	MT
Jefferies Starts Phathom Pharmaceuticals at Buy With $16 Price Target	22-10-21	MT
Needham Adjusts Phathom Pharmaceuticals' Price Target to $38 from $44, Keeps Buy Rating	22-08-03	MT
Goldman Sachs Adjusts Price Target for Phathom Pharmaceuticals to $15 From $32, Retains Neutral Rating	22-05-24	MT
PHATHOM PHARMACEUTICALS : Guggenheim Adjusts Phathom Pharmaceuticals PT to $75 From $66, Maintains Buy Rating	21-10-18	MT
PHATHOM PHARMACEUTICALS : Goldman Sachs Upgrades Phathom Pharmaceuticals to Neutral From Sell, Adjusts Price Target to $48 From $40	21-05-12	MT
PHATHOM PHARMACEUTICALS : BMO Capital Starts Phathom Pharmaceuticals at Outperform With $63 Price Target	21-02-17	MT
PHATHOM PHARMACEUTICALS : Guggenheim Starts Phathom Pharmaceuticals at Buy With $60 Price Target	21-02-02	MT
PHATHOM PHARMACEUTICALS : Needham Adjusts Phathom Pharmaceuticals' Price Target to $55 from $45, Keeps Buy Rating	20-12-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW